We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARIS — Inclisiran, an investigational ...

For the roughly 200 million people worldwide who take a statin every day, the routine is deceptively simple: swallow a pill, repeat tomorrow, repeat forever. In practice, nearly half of patients ...

PHILADELPHIA — A second phase 3 trial with the novel lipid-lowering agent inclisiran (The Medicines Company), which is administered just twice yearly as a subcutaneous injection, have shown impressive ...

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...

Inclisiran’s performance in three large randomized trials is now detailed in two papers published in the New England Journal of Medicine—the previously reported data show LDL cholesterol levels ...

A pooled analysis of clinical trials testing inclisiran (Novartis) confirms the agent’s potent and durable effects on LDL cholesterol and also offers a glimpse of the drug’s potential for lowering the ...

Please provide your email address to receive an email when new articles are posted on . “Inclisiran potentially offers a novel new treatment for LDL,” Weight said here. “Assuming FDA approval, ...

Three phase 3 trials of the novel small-interfering RNA (siRNA) agent inclisiran (The Medicines Company) have been published, all showing an approximate halving of LDL cholesterol levels with the drug ...

https://www.india.com/health/high-cholesterol-what-is-inclisiran-indias-new-approach-to-lower-cholesterol-with-this-two-jabs-a-year-treatment-6655759/ Copy High ...